CSL (OTCMKTS:CSLLY) Reaches New 52-Week High – Still a Buy?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s stock price hit a new 52-week high during trading on Thursday. The stock traded as high as $36.88 and last traded at $36.88, with a volume of 5,472 shares changing hands. The stock had previously closed at $34.64.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research report on Friday, August 7th. Royal Bank Of Canada upgraded shares of CSL from a “hold” rating to a “moderate buy” rating in a research report on Tuesday, September 15th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold”.

CSL Trading Up 0.2%

The firm has a 50 day moving average of $32.26 and a two-hundred day moving average of $29.97. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.21 and a quick ratio of 0.97.

CSL Company Profile

CSL Limited (OTCMKTS:CSLLY) is an Australia-based biotechnology company that develops, manufactures and delivers medicines and vaccines. Its products address a range of serious and chronic conditions, including immune deficiencies, bleeding disorders, respiratory diseases, influenza and iron deficiency.

Through CSL Behring, the company produces plasma-derived and recombinant therapies, including immunoglobulins, albumin and treatments for hemophilia and hereditary angioedema. CSL also operates CSL Seqirus, a major influenza vaccine business that supplies seasonal and pandemic influenza vaccines, as well as other specialty products.